PARylation of HMGA1 desensitizes esophageal squamous cell carcinoma to olaparib
Abstract As a chromatin remodelling factor, high mobility group A1 (HMGA1) plays various roles in both physiological and pathological conditions. However, its role in DNA damage response and DNA damage‐based chemotherapy remains largely unexplored. In this study, we report the poly ADP‐ribosylation...
Saved in:
Main Authors: | Xin‐Yuan Lei, Kai‐Yue He, Qiu‐Tong Li, Lei Zhang, Dan‐Hui Wu, Jing‐Yu Yang, Jin‐Rong Guo, Meng‐Jie Liu, Zi‐Long Zhao, Jun‐Qi Li, Huai Liu, Yuan Zhao, Yu‐Jia Li, Qian‐Hui Sun, Chen‐Guang Wu, Yun‐Fan Wang, Geng‐Sheng Cao, Gang Wang, Yong‐Ping Jian, Zhi‐Xiang Xu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2024-12-01
|
Series: | Clinical and Translational Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/ctm2.70111 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
TOPBP1 as a potential predictive biomarker for enhanced combinatorial efficacy of olaparib and AZD6738 in PDAC
by: Xiao-Mei Tang, et al.
Published: (2025-02-01) -
Cost-effectiveness analysis of durvalumab with chemotherapy and maintenance durvalumab with or without olaparib for advanced endometrial cancer
by: Jiahao Zhang, et al.
Published: (2025-01-01) -
SECTM1 acts as an immune-related biomarker of poor prognosis and promotes cancer progression by modulating M2 macrophage polarization in esophageal squamous cell carcinoma
by: Pengzhou Kong, et al.
Published: (2025-01-01) -
Stem Cell Transplantation for Ovarian Cancer Patient with Associated Myelodysplasia After Maintenance Therapy with Olaparib: A Case Report
by: Linn Z, et al.
Published: (2025-02-01) -
Structural modeling of NAD+ binding modes to PARP-1
by: N. V. Ivanisenko, et al.
Published: (2017-02-01)